Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink

Kayla E. Hanson et al.

Are COVID-19vaccines associated with Guillain-Barré syndrome (GBS)?

In this cohort study of surveillance data from the Vaccine Safety Datalink that included 15.1 million doses of COVID-19 vaccines, the unadjusted incidence rate of confirmed GBS in the 1 to 21 days after receiving the Ad.26.COV2.S (Janssen) vaccine was 32.4 per 100 000 person-years, which was significantly higher than the background rate of GBS. The unadjusted incidence rate of confirmed GBS in the 1 to 21 days after mRNA vaccines was 1.3 per 100 000 person-years, which did not differ from the background rate.

These findings suggest an increased risk of GBS after Ad.26.COV2.S vaccination.

Latest articles

Swiss Policy Research … data from both Germany and Switzerland does show...
Kenji Yamamoto Recently, The Lancet published a study on the effectiveness of...
Kit Knightly Polio is on the front pages of British newspapers again...
Carey Gillam Glyphosate, a synthetic herbicide patented in 1974 by the Monsanto...
Suzanne Burdick A study published last week in Environment International showed 29...

Your donation helps us
stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.

Stay up to date

Sign up to our newsletter to get the latest health-related news and events delivered straight to your inbox.

Become a CHA member

Become an active value-added member and trusted provider of medical and healthcare information and education by joining the CHA Membership Program.

Your donation helps us stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.